Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 20 von 255013
Small (Weinheim an der Bergstrasse, Germany), 2019-12, Vol.15 (51), p.n/a
2019
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Glutathione Depletion in a Benign Manner by MoS2‐Based Nanoflowers for Enhanced Hypoxia‐Irrelevant Free‐Radical‐Based Cancer Therapy
Ist Teil von
  • Small (Weinheim an der Bergstrasse, Germany), 2019-12, Vol.15 (51), p.n/a
Ort / Verlag
Weinheim: Wiley Subscription Services, Inc
Erscheinungsjahr
2019
Quelle
Wiley Online Library - AutoHoldings Journals
Beschreibungen/Notizen
  • Tumor hypoxia significantly diminishes the efficacy of reactive oxygen species (ROS)‐based therapy, mainly because the generation of ROS is highly oxygen dependent. Recently reported hypoxia‐irrelevant radical initiators (AIBIs) exhibit promising potential for cancer therapy under different oxygen tensions. However, overexpressed glutathione (GSH) in cancer cells would potently scavenge the free radicals produced from AIBI before their arrival to the specific site and dramatically limit the therapeutic efficacy. A synergistic antitumor platform (MoS2@AIBI‐PCM nanoflowers) is constructed by incorporating polyethylene‐glycol‐functionalized molybdenum disulfide (PEG‐MoS2) nanoflowers with azo initiator and phase‐change material (PCM). Under near‐infrared laser (NIR) irradiation, the photothermal feature of PEG‐MoS2 induces the decomposition of AIBI to produce free radicals. Furthermore, PEG‐MoS2 can facilitate GSH oxidation without releasing toxic metal ions, greatly promoting tumor apoptosis and avoiding the introduction of toxic metal ions. This is the first example of the use of intelligent MoS2‐based nanoflowers as a benign GSH scavenger for enhanced cancer treatment. Hypoxia‐irrelevant free‐radical initiator (AIBI) has potential for cancer therapy under different oxygen tensions. However, overexpressed glutathione (GSH) in cancer cells would potently scavenge the free radicals produced from AIBI before their arrival to the specific site and dramatically limit the therapeutic efficacy. Therefore, reduction of intracellular GSH level in a benign manner is sorely needed.
Sprache
Englisch
Identifikatoren
ISSN: 1613-6810
eISSN: 1613-6829
DOI: 10.1002/smll.201904870
Titel-ID: cdi_proquest_journals_2328545886

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX